We use cookies to ensure that we give you the best tailored experience on our website based on your preferences. You can read more about our cookie policy here

Innovations in Biomarkers and Diagnostics

Thursday, November 23rd 2017

Add to calendar 2017-11-23 18:00:00 2017-11-23 21:00:00 UTC Innovations in Biomarkers and Diagnostics

The rise of personalised medicine promises tailored treatment to be delivered to the right patients at the right time. This generates parallel demand amongst scientists and clinicians alike – advancing our understanding on patients’ biomarker profiles and developing rapid and accurate diagnostic tools to enable assessment of which patients will benefit from treatment in clinical practice.

Today, there are more personalised medicines than ever before in the clinical pipeline across many disease categories. As of 2015, 1 in 5 FDA approvals were for targeted therapies. Recent years have also witnessed paradigmatic developments in science and technology and streamlining of regulatory pathways and policies, all of which stimulate biomarker discovery, diagnostics development and sustainable innovation towards personalised medicine.

Join us for an evening of talks from academia and industry on innovation in biomarkers and diagnostics, followed by a panel discussion and networking session with the speakers.

52.1982309,0.1248408000000154

18:00 – 21:00 (GMT)

Department of Chemistry

View map

Do you want to attend? Get your ticket!

Register Now

Description

The rise of personalised medicine promises tailored treatment to be delivered to the right patients at the right time. This generates parallel demand amongst scientists and clinicians alike – advancing our understanding on patients’ biomarker profiles and developing rapid and accurate diagnostic tools to enable assessment of which patients will benefit from treatment in clinical practice.

Today, there are more personalised medicines than ever before in the clinical pipeline across many disease categories. As of 2015, 1 in 5 FDA approvals were for targeted therapies. Recent years have also witnessed paradigmatic developments in science and technology and streamlining of regulatory pathways and policies, all of which stimulate biomarker discovery, diagnostics development and sustainable innovation towards personalised medicine.

Join us for an evening of talks from academia and industry on innovation in biomarkers and diagnostics, followed by a panel discussion and networking session with the speakers.

Schedule

18:00-18:20

Registration

18:20-20:30

Talks and Panel discussion

20:30-21:00

Networking

Speakers

Ruth March, PhD, is Senior Vice President of AstraZeneca’s Personalised Healthcare & Biomarkers (PHB) function, leading over 100 diagnostic scientists and experts globally. A member of the senior team in Innovative Medicines and Early Development, Ruth is accountable for delivering diagnostics to drug projects, and also leads AstraZeneca’s Genomics Initiative, analysing genome sequence from up to 2M patients.
She led the build of Personalised Healthcare (PHC) within AstraZeneca, ensuring 80% of clinical drug projects are following a PHC approach. She has achieved 15 diagnostic launches in partnership with diagnostic companies: linked to Iressa (EGFRm tissue and plasma), Lynparza (BRCAm blood and tissue), Tagrisso (EGFRm T790M tissue and plasma) and Zurampic (serum uric acid).
Ruth has pioneered innovation, delivering the world’s first drug label based on circulating tumour DNA (Iressa); first companion diagnostic partnership in next generation sequencing (Illumina); first FDA approval of lab-based companion diagnostic (Lynparza); first diagnostic approval based on both ctDNA and tissue testing (Tagrisso); first point of care diagnostic in gout (Zurampic) and first partnership for asthma point of care diagnostics (AgPlus).
She is a member of Definiens’ Supervisory Board and a genomics specialist with 50 scientific publications and patents.
Ruth spent ten years in immunology and genetics research
at the Universities of London and Oxford. She has over 40 publications and patents in the field of pharmacogenomics and Personalised Healthcare and serves as an expert evaluator for the European Commission.

Dr. Helen Lee is the Director of Research at the Diagnostics Development Unit at Cambridge University, where she leads the development of diagnostics for diseases such as HIV and chlamydia. She is also President and CEO of spin-out company Diagnostics for the Real World, which takes these diagnostics to market.

Clive joins Inivata from Health Innovation Manchester, an initiative to develop an innovation ecosystem involving the decentralisation of £6bn per annum of health and social care services. Previous to this, Clive worked for over a decade in various key roles at AstraZeneca, where he oversaw R&D and medical affairs projects and groups on a global scale, was involved in R&D strategy, investor relations, and most recently led the major transformation of AstraZeneca’s UK strategic R&D sites and global HQ. Clive is a proven leader in the biopharmaceutical industry and has extensive experience across all phases of drug development including seven marketed or close-to-market oncology products. He’s accredited as a Pharmaceutical Medicine specialist by the UK Royal College of Physicians, as well as holding an Executive MBA and Honorary Professorship of Translational Medicine at the University of Manchester. Clive is also a non-executive director of Wheatsheaf investments and the recently launched InnovateUK Medicines Discovery Catapult.

Dr. Jason Mellad (CEO) is the Chief Executive Officer at Cambridge Epigenetix. Before joining the company, he served as Business Development Manager at Horizon Discovery and also has extensive experience in the fields of technology transfer, IP management and product innovation consultancy. Jason has a BSc in Molecular Biology and Chemistry from Tulane University and was a Marshall Scholar at the University of Cambridge where he completed a PhD in Medicine.

Request sponsorship opportunities package

Sponsor this event